| Literature DB >> 34819172 |
Karina Rossi Bonfiglioli1, Licia Maria Henrique da Mota2, Ana Cristina de Medeiros Ribeiro3, Adriana Maria Kakehasi4, Ieda Maria Magalhães Laurindo5, Rina Dalva Neubarth Giorgi6, Angela Luzia Branco Pinto Duarte7, Ana Paula Monteiro Gomides Reis2, Mariana Peixoto Guimarães Ubirajara E Silva de Souza8, Claiton Viegas Brenol9, Geraldo da Rocha Castelar Pinheiro10, Cleandro Pires de Albuquerque2, Charlles Heldan de Moura Castro11, Gustavo Luiz Behrens Pinto12, Jose Fernando Verztman13, Luciana Feitosa Muniz14, Manoel Barros Bertolo15, Maria Raquel da Costa Pinto4, Paulo Louzada Júnior16, Vitor Alves Cruz17, Ivanio Alves Pereira18, Max Vitor Carioca de Freitas19, Bóris Afonso Cruz20, Eduardo Paiva21, Odirlei Monticielo9, José Roberto Provenza22, Ricardo Machado Xavier9.
Abstract
Rheumatoid arthritis (RA) is a chronic and autoimmune systemic inflammatory disease that can cause irreversible joint deformities, with increased morbidity and mortality and a significant impact on the quality of life of the affected individual. The main objective of RA treatment is to achieve sustained clinical remission or low disease activity. However, up to 40% of patients do not respond to available treatments, including bDMARDs. New therapeutic targets for RA are emerging, such as Janus kinases (JAKs). These are essential for intracellular signaling (via JAK-STAT) in response to many cytokines involved in RA immunopathogenesis. JAK inhibitors (JAKi) have established themselves as a highly effective treatment, gaining increasing space in the therapeutic arsenal for the treatment of RA. The current recommendations aim to present a review of the main aspects related to the efficacy and safety of JAKis in RA patients, and to update the recommendations and treatment algorithm proposed by the Brazilian Society of Rheumatology in 2017.Entities:
Mesh：
Substances：
Year: 2021 PMID： 34819172 DOI： 10.1186/s42358-021-00228-x
Source DB: PubMed Journal: Adv Rheumatol ISSN： 2523-3106